Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor. It is marketed as Tarceva for the treatment of locally advanced or metastatic non-small cell lung cancer or pancreatic cancer.